MedPath

KAGAWA UNIVERSITY

KAGAWA UNIVERSITY logo
🇯🇵Japan
Ownership
Private
Established
1949-02-01
Employees
101
Market Cap
-
Website
http://www.ec.kagawa-u.ac.jp

Clinical Trials

59

Active:0
Completed:30

Trial Phases

4 Phases

Phase 1:3
Phase 2:2
Phase 4:2
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials

Not Applicable
49 (87.5%)
Phase 1
3 (5.4%)
Phase 2
2 (3.6%)
Phase 4
2 (3.6%)

Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest

Not Applicable
Recruiting
Conditions
Out-of-hospital Cardiac Arrest (OHCA)
ECMO Treatment
Temperature
Post Cardiac Arrest Syndrome
First Posted Date
2025-01-15
Last Posted Date
2025-06-27
Lead Sponsor
Kagawa University
Target Recruit Count
468
Registration Number
NCT06776549
Locations
🇯🇵

Kurume University Hospital, Kurume, Fukuoka, Japan

🇯🇵

Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan

🇯🇵

Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan

and more 25 locations

Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Not Applicable
Conditions
Epiretinal Membrane
Cataract
Corneal Astigmatism
First Posted Date
2014-12-31
Last Posted Date
2018-03-07
Lead Sponsor
Kagawa University
Target Recruit Count
30
Registration Number
NCT02328157
Locations
🇯🇵

Kagawa University Faculty of Medicine, Miki, Kagawa, Japan

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

Completed
Conditions
Diabetic Macular Edema
First Posted Date
2014-12-31
Last Posted Date
2018-03-08
Lead Sponsor
Kagawa University
Target Recruit Count
30
Registration Number
NCT02329132
Locations
🇯🇵

Kagawa University Faculty of Medicine, Miki, Kagawa, Japan

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Phase 4
Recruiting
Conditions
Macular Disease
Interventions
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin
First Posted Date
2014-12-22
Last Posted Date
2018-03-07
Lead Sponsor
Kagawa University
Target Recruit Count
1000
Registration Number
NCT02321267
Locations
🇯🇵

Kagawa University Faculty of Medicine, Miki, Kagawa, Japan

Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap

Conditions
Chorioretinal Disorders in Diseases Classified Elsewhere
First Posted Date
2014-12-17
Last Posted Date
2018-03-07
Lead Sponsor
Kagawa University
Target Recruit Count
300
Registration Number
NCT02318641
Locations
🇯🇵

Kagawa University Faculty of Medicine, Miki, Kagawa, Japan

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.